{"id":76803,"date":"2026-08-27T14:47:31","date_gmt":"2026-08-27T06:47:31","guid":{"rendered":"https:\/\/flcube.com\/?p=76803"},"modified":"2026-08-27T14:47:32","modified_gmt":"2026-08-27T06:47:32","slug":"hitgen-posts-52-revenue-growth-in-1h-2026-as-del-segment-surges-62-and-recurring-profit-jumps-43","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=76803","title":{"rendered":"HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">China\u2011based <strong>HitGen Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/688222:SHA\">SHA: 688222<\/a>) released its interim report for the first half of 2026, reporting revenue of <strong>RMB 346 million<\/strong>, a year\u2011on\u2011year increase of <strong>52.41%<\/strong>, and recurring net profit attributable to shareholders of <strong>RMB 76.98 million<\/strong>, up <strong>42.80%<\/strong> year on year. Growth was led by the company&#8217;s core <strong>DEL (DNA\u2011encoded library)<\/strong> segment \u2014 boosted by approximately RMB 37 million in IP transfer and milestone fees \u2014 while the <strong>OBT (oligonucleotide\u2011based therapeutics)<\/strong> business nearly doubled, underscoring broad\u2011based momentum across HitGen&#8217;s drug discovery technology platforms.<\/p>\n\n\n\n<h2 id=\"h-financial-highlights-1h-2026\" class=\"wp-block-heading\">Financial Highlights \u2013 1H 2026<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>1H 2026<\/th><th>YoY Change<\/th><\/tr><\/thead><tbody><tr><td>Total Revenue<\/td><td>RMB 346 million<\/td><td>+52.41%<\/td><\/tr><tr><td>Recurring Net Profit (attributable to shareholders)<\/td><td>RMB 76.98 million<\/td><td>+42.80%<\/td><\/tr><tr><td>R&amp;D Investment<\/td><td>RMB 44.90 million<\/td><td>+55.85%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-revenue-by-segment\" class=\"wp-block-heading\">Revenue by Segment<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Segment<\/th><th>Revenue (1H 2026)<\/th><th>YoY Change<\/th><\/tr><\/thead><tbody><tr><td>DEL (DNA\u2011encoded library)<\/td><td>RMB 166 million<\/td><td>+62.14%<\/td><\/tr><tr><td>FBDD\/SBDD (fragment\u2011based \/ structure\u2011based drug design)<\/td><td>RMB 85.09 million<\/td><td>+30.43%<\/td><\/tr><tr><td>OBT (oligonucleotide\u2011based therapeutics)<\/td><td>RMB 54.03 million<\/td><td>+94.03%<\/td><\/tr><tr><td>TPD (targeted protein degradation)<\/td><td>RMB 8.46 million<\/td><td>+12.25%<\/td><\/tr><tr><td>DataSer (data services)<\/td><td>RMB 15.44 million<\/td><td>\u2014<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-segment-highlights-amp-growth-drivers\" class=\"wp-block-heading\">Segment Highlights &amp; Growth Drivers<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>DEL \u2013 Core Engine:<\/strong> The flagship DEL segment reached <strong>RMB 166 million<\/strong> in revenue, up <strong>62.14%<\/strong> year on year, and generated <strong>IP transfer and milestone fees totaling approximately RMB 37 million<\/strong> during the period \u2014 a high\u2011margin contributor to overall profit growth and evidence of HitGen&#8217;s library assets translating into downstream commercial value<\/li>\n\n\n\n<li><strong>OBT \u2013 Fastest Grower:<\/strong> Oligonucleotide\u2011based therapeutics revenue nearly doubled (<strong>+94.03%<\/strong>), reflecting rising global demand for oligonucleotide discovery and development services<\/li>\n\n\n\n<li><strong>FBDD\/SBDD \u2013 Steady Expansion:<\/strong> The fragment\u2011based and structure\u2011based drug design platform grew <strong>30.43%<\/strong>, reinforcing HitGen&#8217;s integrated hit\u2011to\u2011lead offering<\/li>\n\n\n\n<li><strong>TPD \u2013 Emerging Base:<\/strong> Targeted protein degradation revenue grew <strong>12.25%<\/strong>, at an early stage of scaling<\/li>\n\n\n\n<li><strong>DataSer \u2013 New Revenue Stream:<\/strong> Data services contributed <strong>RMB 15.44 million<\/strong>, adding diversification to the revenue mix<\/li>\n\n\n\n<li><strong>R&amp;D Commitment:<\/strong> R&amp;D investment rose <strong>55.85%<\/strong> to RMB 44.90 million, sustaining platform expansion ahead of revenue growth<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Monetization Validated:<\/strong> The combination of 52% top\u2011line growth, 43% recurring profit growth, and RMB 37 million in IP transfer\/milestone fees demonstrates HitGen&#8217;s ability to convert discovery technology into both fee\u2011for\u2011service and asset\u2011based economics.<\/li>\n\n\n\n<li><strong>DEL Franchise Strength:<\/strong> As the world&#8217;s largest DEL ecosystem, HitGen&#8217;s 62% segment growth and milestone harvests reinforce its moat in early\u2011stage drug discovery partnerships with global pharma.<\/li>\n\n\n\n<li><strong>OBT as Second Curve:<\/strong> Near\u2011doubling OBT revenue positions oligonucleotide services as a high\u2011growth second pillar, aligned with the industry\u2011wide surge in RNA therapeutics pipelines.<\/li>\n\n\n\n<li><strong>Watch Items:<\/strong> Conversion of milestone\u2011earning programs into later\u2011stage royalties, OBT capacity expansion and order book, and whether accelerated R&amp;D spending sustains segment growth into the second half.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2013 This brief is for informational purposes only and does not constitute investment advice. Interim results are as reported by the Company; statements regarding future business development and financial performance are forward\u2011looking and subject to risks and uncertainties; actual results may differ materially. Refer to official announcements and filings from HitGen Inc. for authoritative details.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/8fb6b61d449241d0beb6c17281eaa95a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 8fb6b61d449241d0beb6c17281eaa95a.\"><\/object><a id=\"wp-block-file--media-2f8259dc-60fe-4d97-a006-5df1c52b0802\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/8fb6b61d449241d0beb6c17281eaa95a.pdf\">8fb6b61d449241d0beb6c17281eaa95a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/8fb6b61d449241d0beb6c17281eaa95a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-2f8259dc-60fe-4d97-a006-5df1c52b0802\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011based HitGen Inc. (SHA: 688222) released its interim report for the first half of 2026,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":76805,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,4908],"tags":[27,1044,1042],"class_list":["post-76803","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-pic","tag-finanical-reports","tag-hitgen","tag-sha-688222"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43% - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based HitGen Inc. (SHA: 688222) released its interim report for the first half of 2026, reporting revenue of RMB 346 million, a year\u2011on\u2011year increase of 52.41%, and recurring net profit attributable to shareholders of RMB 76.98 million, up 42.80% year on year. Growth was led by the company&#039;s core DEL (DNA\u2011encoded library) segment \u2014 boosted by approximately RMB 37 million in IP transfer and milestone fees \u2014 while the OBT (oligonucleotide\u2011based therapeutics) business nearly doubled, underscoring broad\u2011based momentum across HitGen&#039;s drug discovery technology platforms.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=76803\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%\" \/>\n<meta property=\"og:description\" content=\"China\u2011based HitGen Inc. (SHA: 688222) released its interim report for the first half of 2026, reporting revenue of RMB 346 million, a year\u2011on\u2011year increase of 52.41%, and recurring net profit attributable to shareholders of RMB 76.98 million, up 42.80% year on year. Growth was led by the company&#039;s core DEL (DNA\u2011encoded library) segment \u2014 boosted by approximately RMB 37 million in IP transfer and milestone fees \u2014 while the OBT (oligonucleotide\u2011based therapeutics) business nearly doubled, underscoring broad\u2011based momentum across HitGen&#039;s drug discovery technology platforms.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=76803\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T06:47:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-27T06:47:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2704.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76803#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76803\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%\",\"datePublished\":\"2026-08-27T06:47:31+00:00\",\"dateModified\":\"2026-08-27T06:47:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76803\"},\"wordCount\":506,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76803#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2704.webp\",\"keywords\":[\"Finanical Reports\",\"HitGen\",\"SHA: 688222\"],\"articleSection\":[\"Company\",\"PIC\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76803#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76803\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=76803\",\"name\":\"HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43% - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76803#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76803#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2704.webp\",\"datePublished\":\"2026-08-27T06:47:31+00:00\",\"dateModified\":\"2026-08-27T06:47:32+00:00\",\"description\":\"China\u2011based HitGen Inc. (SHA: 688222) released its interim report for the first half of 2026, reporting revenue of RMB 346 million, a year\u2011on\u2011year increase of 52.41%, and recurring net profit attributable to shareholders of RMB 76.98 million, up 42.80% year on year. Growth was led by the company's core DEL (DNA\u2011encoded library) segment \u2014 boosted by approximately RMB 37 million in IP transfer and milestone fees \u2014 while the OBT (oligonucleotide\u2011based therapeutics) business nearly doubled, underscoring broad\u2011based momentum across HitGen's drug discovery technology platforms.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76803#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76803\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76803#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2704.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2704.webp\",\"width\":1080,\"height\":608,\"caption\":\"HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76803#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43% - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based HitGen Inc. (SHA: 688222) released its interim report for the first half of 2026, reporting revenue of RMB 346 million, a year\u2011on\u2011year increase of 52.41%, and recurring net profit attributable to shareholders of RMB 76.98 million, up 42.80% year on year. Growth was led by the company's core DEL (DNA\u2011encoded library) segment \u2014 boosted by approximately RMB 37 million in IP transfer and milestone fees \u2014 while the OBT (oligonucleotide\u2011based therapeutics) business nearly doubled, underscoring broad\u2011based momentum across HitGen's drug discovery technology platforms.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=76803","og_locale":"en_US","og_type":"article","og_title":"HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%","og_description":"China\u2011based HitGen Inc. (SHA: 688222) released its interim report for the first half of 2026, reporting revenue of RMB 346 million, a year\u2011on\u2011year increase of 52.41%, and recurring net profit attributable to shareholders of RMB 76.98 million, up 42.80% year on year. Growth was led by the company's core DEL (DNA\u2011encoded library) segment \u2014 boosted by approximately RMB 37 million in IP transfer and milestone fees \u2014 while the OBT (oligonucleotide\u2011based therapeutics) business nearly doubled, underscoring broad\u2011based momentum across HitGen's drug discovery technology platforms.","og_url":"https:\/\/flcube.com\/?p=76803","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-27T06:47:31+00:00","article_modified_time":"2026-08-27T06:47:32+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2704.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=76803#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=76803"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%","datePublished":"2026-08-27T06:47:31+00:00","dateModified":"2026-08-27T06:47:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=76803"},"wordCount":506,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=76803#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2704.webp","keywords":["Finanical Reports","HitGen","SHA: 688222"],"articleSection":["Company","PIC"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=76803#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=76803","url":"https:\/\/flcube.com\/?p=76803","name":"HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43% - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=76803#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=76803#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2704.webp","datePublished":"2026-08-27T06:47:31+00:00","dateModified":"2026-08-27T06:47:32+00:00","description":"China\u2011based HitGen Inc. (SHA: 688222) released its interim report for the first half of 2026, reporting revenue of RMB 346 million, a year\u2011on\u2011year increase of 52.41%, and recurring net profit attributable to shareholders of RMB 76.98 million, up 42.80% year on year. Growth was led by the company's core DEL (DNA\u2011encoded library) segment \u2014 boosted by approximately RMB 37 million in IP transfer and milestone fees \u2014 while the OBT (oligonucleotide\u2011based therapeutics) business nearly doubled, underscoring broad\u2011based momentum across HitGen's drug discovery technology platforms.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=76803#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=76803"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=76803#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2704.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2704.webp","width":1080,"height":608,"caption":"HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=76803#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2704.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76803","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=76803"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76803\/revisions"}],"predecessor-version":[{"id":76806,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76803\/revisions\/76806"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/76805"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=76803"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=76803"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=76803"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}